Tenaya Therapeutics Inc (TNYA)
4.54
-0.14
(-2.99%)
USD |
NASDAQ |
May 06, 16:00
4.54
0.00 (0.00%)
After-Hours: 20:00
Tenaya Therapeutics Research and Development Expense (Quarterly): 22.86M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 22.86M |
| September 30, 2023 | 23.09M |
| June 30, 2023 | 26.48M |
| March 31, 2023 | 25.60M |
| December 31, 2022 | 25.75M |
| September 30, 2022 | 23.76M |
| June 30, 2022 | 20.88M |
| March 31, 2022 | 24.16M |
| Date | Value |
|---|---|
| December 31, 2021 | 20.95M |
| September 30, 2021 | 12.94M |
| June 30, 2021 | 10.91M |
| March 31, 2021 | 9.59M |
| December 31, 2020 | 8.364M |
| September 30, 2020 | 8.48M |
| June 30, 2020 | 6.958M |
| March 31, 2020 | 7.297M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
6.958M
Minimum
Jun 2020
26.48M
Maximum
Jun 2023
17.38M
Average
20.91M
Median
Research and Development Expense (Quarterly) Benchmarks
| Adverum Biotechnologies Inc | 15.28M |
| Solid Biosciences Inc | 15.45M |
| Dyne Therapeutics Inc | 44.54M |
| Sana Biotechnology Inc | 69.84M |
| Prime Medicine Inc | 41.46M |